Symbols

AMRX

Amneal·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

Gap Up

Low Cash Short-term Debt Ratio

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AMRX

Amneal Pharmaceuticals, Inc.

A manufacturer engaged in the development and production of high-value generic pharmaceutical products

Industry

Pharmaceutical

Established Date

Listing Date

12/27/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

8,500

Fiscal Year Ends

12-31

Website

www.amneal.com

Security Type

Common stock

Office address

400 Crossing Boulevard, Bridgewater, NJ 08807

Business

Introduction

Amneal Pharmaceuticals, Inc., is a Delaware corporation. The company is a diversified global biopharmaceutical business that develops, manufactures, markets and distributes a broad portfolio of pharmaceuticals. It operates through three divisions: the general drug division, which includes retail generic drugs and injections; the specialty drug division, which focuses on brand-name drugs for central nervous system and endocrine diseases; and the AvKARE division, which provides distribution services for the US government and retail markets.

Company Financials

EPS

AMRX has released its 2025 Q4 earnings. EPS was reported at 0.21, versus the expected 0.18, beating expectations. The chart below visualizes how AMRX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AMRX has released its 2025 Q4 earnings report, with revenue of 814.32M, reflecting a YoY change of 11.47%, and net profit of 49.57M, showing a YoY change of 339.00%. The Sankey diagram below clearly presents AMRX's revenue sources and cost distribution.